- Home
- JFU vs ATHA Comparison
JFU vs ATHA Comparison
Compare JFU & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- ATHA
- Stock Information
- Founded
- JFU 2006
- ATHA 2011
- Country
- JFU China
- ATHA United States
- Employees
- JFU N/A
- ATHA N/A
- Industry
- JFU Finance: Consumer Services
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- JFU Finance
- ATHA Health Care
- Exchange
- JFU Nasdaq
- ATHA Nasdaq
- Market Cap
- JFU 17.1M
- ATHA 14.8M
- IPO Year
- JFU 2019
- ATHA 2020
- Fundamental
- Price
- JFU $1.83
- ATHA $0.40
- Analyst Decision
- JFU
- ATHA Buy
- Analyst Count
- JFU 0
- ATHA 4
- Target Price
- JFU N/A
- ATHA $11.25
- AVG Volume (30 Days)
- JFU 14.0K
- ATHA 198.5K
- Earning Date
- JFU 01-01-0001
- ATHA 08-07-2025
- Dividend Yield
- JFU N/A
- ATHA N/A
- EPS Growth
- JFU N/A
- ATHA N/A
- EPS
- JFU 0.58
- ATHA N/A
- Revenue
- JFU $42,467,427.00
- ATHA N/A
- Revenue This Year
- JFU N/A
- ATHA N/A
- Revenue Next Year
- JFU N/A
- ATHA N/A
- P/E Ratio
- JFU $3.45
- ATHA N/A
- Revenue Growth
- JFU N/A
- ATHA N/A
- 52 Week Low
- JFU $1.01
- ATHA $0.22
- 52 Week High
- JFU $3.60
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- JFU 58.35
- ATHA 54.38
- Support Level
- JFU $1.53
- ATHA $0.36
- Resistance Level
- JFU $2.10
- ATHA $0.41
- Average True Range (ATR)
- JFU 0.14
- ATHA 0.03
- MACD
- JFU 0.03
- ATHA -0.00
- Stochastic Oscillator
- JFU 53.45
- ATHA 81.60
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.